Iressa | Tocris Bioscience 3000 product information

product summary

company name :

Tocris Bioscience

product type :

chemical

product name :

Iressa

catalog :

3000

quantity :

10 mg (also 50 mg)

price :

159 USD

more info or order :

Tocris Bioscience product webpage

citations: 21

Reference
Suina K, Tsuchihashi K, Yamasaki J, Kamenori S, Shintani S, Hirata Y, et al. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. Cancer Sci. 2018;109:3874-3882 pubmed publisher
Zhu X, Jiang H, Li J, Xu J, Fei Z. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer. Med Sci Monit. 2016;22:1435-41 pubmed
Staberg M, Michaelsen S, Olsen L, Nedergaard M, Villingshøj M, Stockhausen M, et al. Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell Int. 2016;16:34 pubmed publisher
Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, et al. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol. 2016;48:1825-36 pubmed publisher
Oda M, Iwaya K, Kikuchi R, Kobayashi T, Yoneda T, Nishikawa K, et al. Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro. J Bone Oncol. 2012;1:40-6 pubmed publisher
Li L, Huang W, Li K, Zhang K, Lin C, Han R, et al. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget. 2015;6:43605-19 pubmed publisher
Lindholm P, Sivapurapu N, Jovanovic B, Kajdacsy Balla A. Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-ÎºB Activity. J Clin Cell Immunol. 2015;6: pubmed
Curran S, Vantangoli M, Boekelheide K, Morgan J. Architecture of Chimeric Spheroids Controls Drug Transport. Cancer Microenviron. 2015;8:101-9 pubmed publisher
Kleczko E, Kim J, Keysar S, Heasley L, Eagles J, Simon M, et al. An Inducible TGF-?2-TGF?R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS ONE. 2015;10:e0123600 pubmed publisher
Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, et al. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget. 2015;6:9173-88 pubmed
Moody T, Nuche Berenguer B, Moreno P, Jensen R. CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells. J Mol Neurosci. 2015;56:663-72 pubmed publisher
Wang X, Song H, Yu Q, Liu Q, Wang L, Liu Z, et al. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. Oncol Rep. 2015;33:526-32 pubmed publisher
Qawasmi I, Shmuel M, Eyal S. Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging. Front Pharmacol. 2014;5:257 pubmed publisher
Sakurai M, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS ONE. 2014;9:e100124 pubmed publisher
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res. 2014;20:2714-26 pubmed publisher
Moody T, Chan D, Mantey S, Moreno P, Jensen R. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner. Life Sci. 2014;100:25-34 pubmed publisher
Joannes A, Grelet S, Duca L, Gilles C, Kileztky C, Dalstein V, et al. Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. Mol Cancer Res. 2014;12:775-83 pubmed publisher
Kitazono S, Takiguchi Y, Ashinuma H, Saito Kitazono M, Kitamura A, Chiba T, et al. Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol. 2013;43:1846-54 pubmed publisher
Bichsel K, Gogia N, Malouff T, Pena Z, Forney E, Hammiller B, et al. Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS ONE. 2013;8:e69368 pubmed publisher
Edris B, Fletcher J, West R, van de Rijn M, Beck A. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma. 2012;2012:805614 pubmed publisher
McMellen M, Wakeman D, Erwin C, Guo J, Warner B. Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery. 2010;148:364-70 pubmed publisher

product information

brand :

Tocris

master code :

3000

SKU :

3000/10

product name :

Iressa

description :

Orally active, selective EGFR inhibitor

target :

EGF Receptor Inhibitors

category :

Small Molecules

unit size :

10 mg (also 50 mg)

purity :

98%

observed molecular weight :

446.9

url print :

?utm_source=distributor&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

details of functionality :

Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts. Also inhibits growth of brain metastases in mouse model of non-small cell lung cancer. . View information regarding the usage of Iressa for non-clinical studies .

catalog number base :

3000

product keywords :

Orally active selective EGFR inhibitors inhibits Epidermal Growth Factors Receptors ErbB Her Receptor Tyrosine Kinases RTKs AstraZeneca ZD1839 chemotherapeutics Gefitinib ZD 1839 EGFR 3000,

extended description :

Orally active, selective EGFR inhibitor

chemical name text :

N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine

formula :

C 22 H 24 ClFN 4 O 3

formula text :

C22H24ClFN4O3

cas num :

184475-35-2

2020 USD :

155

2021 USD :

159 USD

alt names :

Gefitinib, ZD 1839

storage :

Store at RT

more info or order :

Tocris Bioscience product webpage